Can serum neural autoantibodies alone establish autoimmune encephalitis?

Serum neural-autoantibody results are increasingly encountered during evaluation of cognitive and neuropsychiatric symptoms, particularly in older adults. Their clinical significance depends on concordance with an encephalitic syndrome and objective evidence of central nervous system involvement—not on serum positivity alone.

Clinical and diagnostic evidence

• Autoimmune encephalitis is a clinicoparaclinical diagnosis. Possible disease requires a compatible subacute syndrome (for example, new working-memory impairment, altered mental status, or psychiatric symptoms), at least one supportive finding, and reasonable exclusion of alternative causes.
• Serum-only antibody detection does not establish autoimmune encephalitis. In a routine diagnostic cohort, only 31% of serum-only positive results were considered clinically relevant, versus 91% of CSF-only positives.
• In dementia populations, isolated serum NMDAR antibodies have not shown an overall association with typical dementia or Alzheimer-type disease. Among serum-positive dementia cases with CSF testing, only about 2% were CSF-positive; a 920-person neurodegenerative-dementia cohort found confirmed neuronal antibodies uncommon, with no MRI findings suggestive of autoimmune encephalitis.

Assay, compartment, and ancillary testing

• Weak, low-titre, phenotype-discordant, or serum-only reactivity can be misleading. Assay platform, dilution, interpretation expertise, and confirmatory methodology materially affect the meaning of a positive result.
• Paired serum and CSF testing before immunotherapy is preferred when autoimmune encephalitis is suspected. CSF is particularly informative for NMDAR and GFAP antibodies, whereas serum may be more sensitive for LGI1 and CASPR2.
• CSF pleocytosis, encephalitis-pattern MRI abnormalities, EEG evidence of seizures or focal dysfunction, and—in selected cases—FDG-PET can strengthen diagnostic confidence. Normal CSF, MRI, or EEG does not independently exclude disease.

Bottom line

• A positive serum neural autoantibody should prompt phenotype-directed confirmation and evaluation, not automatic attribution of cognitive decline to autoimmune encephalitis or the antibody itself.